Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02899052
- Locations
- 🇺🇸
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
🇺🇸University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 124
- Registration Number
- NCT02891811
- Locations
- 🇦🇹
Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria
🇦🇹Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria
🇦🇹Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 14
- Registration Number
- NCT02867618
- Locations
- 🇺🇸
Columbia University Irving Medical Center - Center for Lymphoid Malignancies, New York, New York, United States
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
- Conditions
- Interventions
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 466
- Registration Number
- NCT02773030
- Locations
- 🇺🇸
Local Institution - 101, Atlanta, Georgia, United States
🇺🇸Local Institution - 108, Hackensack, New Jersey, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 180
- Registration Number
- NCT02659293
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Wayne State University - Karmanos Cacner Institute, Detroit, Michigan, United States
🇵🇱Polish Myeloma Consortium, Poznań, Poland
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Registration Number
- NCT02628704
- Locations
- 🇺🇸
James R. Berenson MD, Inc, West Hollywood, California, United States
🇺🇸Waverly Hematology, Cary, North Carolina, United States
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 76
- Registration Number
- NCT02597062
- Locations
- 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- University College, London
- Target Recruit Count
- 10
- Registration Number
- NCT02545907
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, Devon, United Kingdom
🇬🇧Royal Bournemouth General Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧Southampton General Hospital, Southampton, Hampshire, United Kingdom
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
- Conditions
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 4
- Registration Number
- NCT02512926
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.